Gainers
Statera Biopharma, Inc. (NASDAQ: STAB) rose 30.4% to $0.9520 in pre-market trading. Statera Biopharma recently submitted Phase 1 clinical trial protocol to the FDA for investigational treatment of long-haul COVID-19.
DSS, Inc. (“DSS” or the “Company”) (NYSE:DSS), a multinational company with nine operating business lines in diverse, high-growth industries, entered into a stock purchase agreement (the
Gainers
Exterran Corporation (NYSE: EXTN) shares surged 59.7% to close at $4.79 on Monday after the company said it would merge with Enerflex to create a premier integrated global provider of energy infrastructure.